Home » Newsletters » BioWorld Science

BioWorld Science

June 18, 2002

View Archived Issues

Novel anticholinergics and their use in asthma, COPD, etc.

Boehringer Ingelheim claims new agents for urinary incontinence

DPP-IV inhibitors and their use in diabetes and related disorders reported by Tanabe

Shionogi develops novel MMP inhibitors

Yamanouchi presents mGluR1 modulators useful in stroke

cGMP-selective PDE inhibitors in early development at Nippon Soda

Preclinical profile of AZD-3582 highlighted at EULAR 2002

Japanese approval obtained for Elaspol

Virucidal activity of liposomal povidone-iodine

Antioxidant and cardioprotective effects of resveratrol and astringinin

MEDICA 16 inhibits hepatic acetyl-CoA carboxylase in insulin-resistant rats

Significant beneficial effects on health-related QOL seen in RA patients treated with CDP-870

Pegylated Axokine enters phase I for treatment of obesity

Patent coverage obtained for Mindset's lead AD therapeutic candidate

Improvement in glucose tolerance in ZDF rats treated with NVP-DPP-728

FDA approves Celebrex labeling changes

Pfizer to return rights to UK-279276 to Corvas

Miltefosine designated an orphan drug for black fever

Essential Therapeutics updates development program objectives

Antidiabetic activity of PPARgamma ligand related to effects on DPP-IV

Chromium supplementation lowers blood glucose, insulin requirements in type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...